Found: 10
Select item for more details and to access through your institution.
First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll‐like Receptors 7 and 8, in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 4, p. 363, doi. 10.1002/cpdd.1176
- By:
- Publication type:
- Article
Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial.
- Published in:
- Journal of Dermatology, 2016, v. 43, n. 8, p. 881, doi. 10.1111/1346-8138.13231
- By:
- Publication type:
- Article
Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: Results of a randomized, vehicle-controlled, multicenter clinical trial.
- Published in:
- Journal of Dermatology, 2014, v. 41, n. 7, p. 577, doi. 10.1111/1346-8138.12534
- By:
- Publication type:
- Article
Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study.
- Published in:
- Arthritis & Rheumatology, 2021, v. 73, n. 4, p. 587, doi. 10.1002/art.41555
- By:
- Publication type:
- Article
Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate.
- Published in:
- Modern Rheumatology, 2024, v. 34, n. 1, p. 37, doi. 10.1093/mr/road004
- By:
- Publication type:
- Article
Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs.
- Published in:
- Modern Rheumatology, 2024, v. 34, n. 1, p. 45, doi. 10.1093/mr/road005
- By:
- Publication type:
- Article
A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological diseasemodifying antirheumatic drugs.
- Published in:
- Modern Rheumatology, 2021, v. 31, n. 4, p. 783, doi. 10.1080/14397595.2020.1868675
- By:
- Publication type:
- Article
Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis.
- Published in:
- Modern Rheumatology, 2018, v. 28, n. 1, p. 58, doi. 10.1080/14397595.2017.1337056
- By:
- Publication type:
- Article
Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men.
- Published in:
- Innate Immunity, 2012, v. 18, n. 6, p. 793, doi. 10.1177/1753425912441845
- By:
- Publication type:
- Article
Cisplatin-induced inhibition of receptor-mediated endocytosis of protein in the kidney.
- Published in:
- Kidney International, 2002, v. 62, n. 5, p. 1707, doi. 10.1046/j.1523-1755.2002.00623.x
- By:
- Publication type:
- Article